On Wednesday, Shares of Cypress Semiconductor Corporation (NASDAQ:CY), lost -2.59% to $9.76.
Cypress Semiconductor Corp., declared that its EZ-PD CCG1 and EZ-PD CCG2 USB Power Delivery (PD) controllers passed the USB Implementers Forum (USB-IF) certification test procedure for USB Type-C™ DRP (Dual Role Port), DFP (Downstream Facing Port), and UFP (Upstream Facing Port) applications. The Cypress controllers received approved Product Test IDs 1096037, 1096039, 1096040, 1096042, 1096044 and 1096047 at the recently concluded USB-IF Compliance Workshop event held in Portland, Oregon. EZ-PD controllers address a broad set of market segments such as USB Type-C Notebooks, Power Adapters, Monitors, Docks, Cables, and Cable Adapters (dongles). Cypress is demonstrating its EZ-PD controllers and EZ-USB SuperSpeed USB portfolio here at the Intel Developer Forum at booth number 910 in the USB Community from August 18-20, 2015.
Cypress’s EZ-PD CCG1 and second-generation EZ-PD CCG2 controllers each formerly achieved certification for USB Power Delivery (PD) E-Marker capabilities and were assigned Product Test IDs 1095054 and 1095059. E-Marker chips are used in USB Power Delivery cables, counting USB Type-C, to report the characteristics a cable supports, such as current-carrying capability, protocols supported and vendor identification. The USB Type-C standard is gaining rapid support with top-tier PC and electronics manufacturers by enabling slim industrial designs, easy-to-use connectors and cables, and the ability to transmit multiple protocols and deliver up to 100W of power. The USB Type-C standard’s 2.4-mm-high connector plug is significantly smaller than current 4.5-mm USB Standard-A connector. In addition to the transport of USB signals, DisplayPort and Mobile High-Definition Link (MHL) signals may be delivered over the same connector via the USB Type-C Alternate Mode capability.
“The combination of USB 3.1 Gen 2, USB Type-C and USB Power Delivery are enabling new performance, connectivity and charging usage models to a wide range of computing and mobile applications with a single cable solution for performance, power and convenience,” said Jeff Ravencraft, USB-IF President and COO. “USB-IF certification is essential to ensuring that a product is compliant with the highest standard in the industry and that it will interoperate with all other products identified with the same certified logo. Products that achieve USB-IF certification, such as Cypress’s flexible EZ-PD CCG1 and CCG2 controllers, bring USB Power Delivery and a seamless user experience for emerging USB Type-C products.”
Cypress Semiconductor Corporation provides mixed-signal programmable solutions, semiconductor memories, and integrated semiconductor solutions worldwide. The company’s Memory Products division designs and manufactures static random access memory (SRAM) products and nonvolatile RAMs used to store and retrieve data in networking, wireless infrastructure and handsets, computation, consumer, automotive, industrial, and other electronic systems; and general-purpose programmable clocks.
Shares of Gold Fields Limited (ADR) (NYSE:GFI), inclined 8.93% to $3.05, during its last trading session.
Gold Fields Limited, declared net earnings attributable to our shareholders of US$12 million for the June 2015 quarter contrast with net losses of US$14 million in the March 2014 quarter and net earnings of US$19 million in the June 2014 quarter. Normalized earnings of US$22 million for the June 2015 quarter contrast with normalized losses of US$13 million in the March 2014 quarter and normalized earnings of US$25 million in the June 2014 quarter.
Interim dividend of 4 SA cents per share is payable on 14 September 2015
Gold Fields Limited operates as a gold mining company. The company engages in the exploration, extraction, processing, and smelting of gold and copper properties. It holds interests in eight operating mines in South Africa, Ghana, Australia, and Peru.
Finally, ABIOMED, Inc. (NASDAQ:ABMD), ended its last trade with -0.36% loss, and closed at $104.55.
Abiomed, declared that it has presented U.S Food & Drug Administration (FDA) pre-market approval (PMA) supplemental submissions requesting to expand Impella 2.5 PMA approval to all of the Impella family of devices (Impella 2.5, Impella CP and Impella 5.0/LD). The submissions are for a set of indications related to the use of the Impella devices in patients suffering cardiogenic shock following acute myocardial infarction or cardiac surgery. A request for a longer duration of support is also comprised of.
These submissions are projected as a supplement to the Impella 2.5 PMA approval for high-risk percutaneous coronary intervention (PCI) received on March 23, 2015, and comprise analysis on 415 patients from the FDA study RECOVER 1 and the U.S. Impella registry, and a relevant Impella literature review that references 692 patients in 17 clinical studies. Additionally, over 24,000 Impella patients supported by Impella devices were reviewed in a safety analysis offered using the FDA/Medical Device Reporting (MDR) database.Through its review of the supplemental submission, the FDA will ultimately render a decision concerning the safety and efficacy of the Impella CP and the Impella 5.0 in the applied-for patient populations.
ABIOMED, Inc. researches, develops, and sells medical devices in circulatory support and continuum of care in heart recovery to acute heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
